Symbiotec Pharmalab — Subscription Status

live subscription status by category — QIB, NII, retail, employee and shareholder — with shares offered, bids received and demand value.

Symbiotec Pharmalab logo
LISTEDMAINBOARDEquity

Symbiotec Pharmalab

Price band
₹938 – ₹988
Lot size
15 shares
Min investment
₹14,820
Issue size
₹1,757 Cr
Total
71.26×
QIB
172.03×
NII / HNI
73.63×
Retail
12.96×
Employee
15.41×
Applications
51,73,193

Subscription by category

Category-wise bids

CATEGORYTIMESSHARES OFFEREDSHARES BIDAPPLICATIONSDEMAND (₹ CR)
Qualified Institutional Buyers (QIB)172.03×37,39,87264,33,59,19522663,563.89
↳ Foreign Institutional Investors——12,59,47,230—12,443.59
↳ Domestic Financial Institutions——36,76,69,110—36,325.71
↳ Mutual Funds——3,49,90,815—3,457.09
↳ Others——11,47,52,040—11,337.5
Non-Institutional Investors (NII)73.63×28,04,90420,65,35,1203,85,63220,405.67
↳ bNII — bids above ₹10 Lakh82.92×18,69,93615,50,46,4951,49,63615,318.59
↳ bNII — Corporates——12,53,805—123.88
↳ bNII — Individuals——14,63,23,875—14,456.8
↳ bNII — Others——74,68,815—737.92
↳ sNII — bids ₹2 Lakh to ₹10 Lakh55.07×9,34,9685,14,88,6252,35,9965,087.08
↳ sNII — Corporates——1,44,720—14.3
↳ sNII — Individuals——4,95,61,725—4,896.7
↳ sNII — Others——17,82,180—176.08
Retail Individual Investors (RII)12.96×65,44,7768,48,10,33047,86,7598,379.26
↳ Cut-off price bids——7,22,08,140—7,134.16
↳ Price bids——1,26,02,190—1,245.1
Employee15.41×35,3775,45,05557653.85
↳ Cut-off price bids——4,55,625—45.02
↳ Price bids——89,430—8.84
Shareholder0.00×—0—0
↳ Cut-off price bids—————
↳ Price bids—————
Total71.26×1,31,24,92993,52,49,70051,73,19392,402.67

Updated 01 Sep 2026, 06:31 PM IST • demand at ₹988

QIB interest cost

Estimated cost for QIB bidders funding 1,69,965.64 per share for 7 days at ₹988.

RATECOST / SHARECOST %
7%₹228.1723.09%
8%₹260.7726.39%
9%₹293.3729.69%
10%₹325.9632.99%
11%₹358.5636.29%
12%₹391.1539.59%

Want the day-by-day picture? See day-wise subscription history.

Data refreshed 07 Nov 2026, 05:03 pm IST. GMP is unofficial market sentiment, not investment advice.